Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Furnari

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Neuro-Oncology Advances|August 9, 2024
Glioblastoma vulnerability to neddylation inhibition is dependent on PTEN status, and dysregulation of the cell cycle and DNA replicationBrett Taylor, Nanyun Tang, Yue Hao, et al.
Genes & Development|August 18, 2010
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastomaMaria-del-Mar Inda, Rudy Bonavia, Akitake Mukasa, et al.
Neuro-Oncology|January 11, 2021
PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastomaJorge A Benitez, Darren Finlay, Anthony Castanza, et al.
Cancer Research|May 14, 2009
EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastomaBipasha Mukherjee, Brian McEllin, Cristel V Camacho, et al.
Oncotarget|March 25, 2014
Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastomaJie Li, Shan Zhu, David Kozono, et al.
Neuro-Oncology|March 19, 2022
PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitorsShayesteh R Ferdosi, Brett Taylor, Matthew Lee, et al.
Cell Death and Differentiation|December 2, 2022
Caspase-8 as a novel mediator linking Src kinase signaling to enhanced glioblastoma malignancyClaudia Contadini, Alessandra Ferri, Marta Di Martile, et al.
Plos One|June 10, 2010
Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapyMasayuki Nitta, David Kozono, Richard Kennedy, et al.
Cancer Cell|April 9, 2008
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma developmentRuprecht Wiedemeyer, Cameron Brennan, Timothy P Heffernan, et al.
Genes & Development|April 18, 2012
Emerging insights into the molecular and cellular basis of glioblastomaGavin P Dunn, Mikael L Rinne, Jill Wykosky, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Neuro-Oncology Advances|August 9, 2024
Glioblastoma vulnerability to neddylation inhibition is dependent on PTEN status, and dysregulation of the cell cycle and DNA replicationBrett Taylor, Nanyun Tang, Yue Hao, et al.
Genes & Development|August 18, 2010
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastomaMaria-del-Mar Inda, Rudy Bonavia, Akitake Mukasa, et al.
Neuro-Oncology|January 11, 2021
PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastomaJorge A Benitez, Darren Finlay, Anthony Castanza, et al.
Cancer Research|May 14, 2009
EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastomaBipasha Mukherjee, Brian McEllin, Cristel V Camacho, et al.
Oncotarget|March 25, 2014
Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastomaJie Li, Shan Zhu, David Kozono, et al.
Neuro-Oncology|March 19, 2022
PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitorsShayesteh R Ferdosi, Brett Taylor, Matthew Lee, et al.
Cell Death and Differentiation|December 2, 2022
Caspase-8 as a novel mediator linking Src kinase signaling to enhanced glioblastoma malignancyClaudia Contadini, Alessandra Ferri, Marta Di Martile, et al.
Plos One|June 10, 2010
Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapyMasayuki Nitta, David Kozono, Richard Kennedy, et al.
Cancer Cell|April 9, 2008
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma developmentRuprecht Wiedemeyer, Cameron Brennan, Timothy P Heffernan, et al.
Genes & Development|April 18, 2012
Emerging insights into the molecular and cellular basis of glioblastomaGavin P Dunn, Mikael L Rinne, Jill Wykosky, et al.
Pageof 4